Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 236,697,120 papers from all fields of science
Search
Sign In
Create Free Account
tanezumab
A humanized monoclonal antibody directed against nerve growth factor (NGF), a modulator of nociceptor function, with potential analgesic activity…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
Broader (1)
Antibodies, Monoclonal, Humanized
Narrower (2)
PF 4383119
RN 624
antigen binding
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Is Tanezumab More Effective than a Placebo in Reducing Pain in Patients with Osteoarthritis
N. Rivera
2018
Corpus ID: 86835744
OBJECTIVE: The objective of this selective EBM review is to determine whether or not, “Is tanezumab more effective than a placebo…
Expand
2015
2015
NGF-Hemmer Tanezumab lindert neuropathischen Schmerz
C. Bramson
,
D. Herrmann
,
+5 authors
P. J. Dyck
Journal Club Schmerzmedizin
2015
Corpus ID: 148176233
Bei der Weiterleitung von Schmerzsignalen spielt der Nerve Growth Factor (NGF) eine zentrale Rolle. NGF moduliert nach Bindung an…
Expand
2015
2015
Tanezumab bei chronischer Lumbalgie?
J. Gimbel
,
Alan J. Kivitz
,
+5 authors
Kenneth M. Verburg
Journal Club Schmerzmedizin
2015
Corpus ID: 80451611
Bei Tanezumab handelt es sich um einen humanisierten monoklonalen Antikörper gegen den Nerve Growth Factor (NGF), der…
Expand
2015
2015
Tanezumab clinical trials to resume
C. Blank
2015
Corpus ID: 70448166
Pfizer and Eli Lilly and Company said they will resume Phase 3 clinical studies for tanezumab for chronic pain, after the Food…
Expand
2015
2015
Antikörper gegen Kreuzschmerz
B. Schumacher
Schmerzmedizin
2015
Corpus ID: 41428686
Chronische Schmerzen im Lumbalbereich lassen sich durch eine Behandlung mit dem Antikörper Tanezumab längerfristig bessern…
Expand
2013
2013
Tanezumab Reduces Hip OA Pain, Improves Function
Rheumatologynetwork Staff
2013
Corpus ID: 155499136
In phase 3 trials, the nerve growth factor inhibitor tanezumab significantly relieved the pain of hip osteoarthritis, compared to…
Expand
2013
2013
randomised clinical trial parallel-group , multicentre phase III double-blind , placebo-controlled , with knee or hip osteoarthritis : a to diclofenac sustained release in patients Efficacy and…
A. Bălănescu
,
E. Feist
,
+4 authors
C. West
2013
Corpus ID: 207767283
These include: Data Supplement http://ard.bmj.com/content/suppl/2013/07/12/annrheumdis-2012-203164.DC1.html "Supplementary Data…
Expand
2013
2013
Pfizer Mitigates Tanezumab Risk with Potential US$1.8 B Deal with Eli Lilly
Heather Cartwright
2013
Corpus ID: 70397535
Three years after development of the entire class of nerve growth factor (NGF) inhibitors was put on clinical hold by the US FDA…
Expand
2011
2011
Novel agents combined get own guidance
Nature Biotechnology
2011
Corpus ID: 46195162
volume 29 number 3 mArCH 2011 nature biotechnology Victoria, Australia, in an e-mail. Grills, who performed the rat fracture…
Expand
2010
2010
Population Pharmacokinetics of a Monoclonal Antibody Tanezumab in Chronic Pelvic Pain Conditions
A. Cleton
,
Bojan Lalovic
,
R. Xie
,
R. Arends
2010
Corpus ID: 74623651
Results An IV infusion, 2-compartment model with parallel linear and nonlinear (Michaelis-Menten) elimination pathways adequately…
Expand